Download File - JOHN J. HADDAD, Ph.D.

Peptide-Based Active Immunotherapy in Cancer 127
prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res
2007; 16(7):341–349.
58. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in
normal humans using primary cultures and synthetic peptide epitopes. Proc Natl
Acad Sci U S A 1994; 91:2105–2109.
59. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic
vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic
T lymphocyte response in humans. J Clin Invest 1995; 95:341–349.
60. Sette A, Alexander J, Ruppert J, et al. Antigen analogs/MHC complexes as specific
T cell receptor antagonists. Annu Rev Immunol 1994; 12:413–431.
61. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanomareactive
CTL with peptides from the melanoma antigen gp100 modified at HLA-
A*0201-binding residues. J Immunol 1996; 157:2539–2548.
62. Eguchi J, Hatano M, Nishimura F, et al. Identification of interleukin-13 receptor
alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Cancer Res 2006; 66(11):5883–5891.
63. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced
by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic
melanoma. Proc Natl Acad Sci U S A 2003; 100(14):8372–8377.
64. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully
human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple
melanoma peptides and Montanide ISA 51 for patients with resected stages III and
IV melanoma. J Clin Oncol 2005; 23(4):741–750.
65. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with
incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res
1999; 5(10):2756–2765.
66. Jeager E, Maeurer M, Heohn H, et al. Clonal expansion of Melan A-specific cytotoxic
T lymphocytes in a melanoma patient responding to continued immunization
with melanoma-associated peptides. Int J Cancer 2000; 86(4):538–547.
67. Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al. Terminal modifications
inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications
for peptide vaccines. Int J Cancer 1999; 83(3):326–334.
68. Minev BR, Chavez FL, Dudouet BM, et al. Synthetic insertion signal sequences
enhance MHC class I presentation of a peptide from the melanoma antigen MART-1.
Eur J Immunol 2000; 30:2115–2124.
69. Anderson K, Cresswell P, Gammon M, et al. Endogenously synthesized peptide with
an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells
to class I-restricted cell-mediated lysis. J Exp Med 1991; 174:489–492.
70. Okada CY, Rechsteiner M. Introduction of macromolecules into cultured mammalian
cells by osmotic lysis of pinocytic vesicles. Cell 1982; 29:33–41.
71. Persson H, Jornvall H, Zabielski J. Multiple mRNA species for the precursor to an
adenovirus-encoded glycoprotein: identification and structure of the signal sequence.
Proc Natl Acad Sci U S A 1980; 77:6349–6353.
72. Houghton M, Stewart AG, Doel SM, et al. The amino-terminal sequence of human
fibroblast interferon as deduced from reverse transcripts obtained using synthetic
oligonucleotide primers. Nucleic Acids Res 1980; 8:1913–1931.
73. Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class
I-restricted peptides. Annu Rev Biochem 1995; 64:463–491.